New drugs for chronic myelogenous leukemia

Current Hematologic Malignancy Reports

Volumn 6, Issue 2, 2011, Pages 96-103

  Santos, Fabio P S ^b   Quintás Cardama, Alfonso ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Aurora kinase inhibitors; Chronic myeloid leukemia; Homoharringtonine; Ponatinib; Tyrosine kinase inhibitors

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ADENOSINE TRIPHOSPHATE; ALVESPIMYCIN; AURORA C KINASE; AURORA KINASE INHIBITOR; DANUSERTIB; DCC 2036; FINGOLIMOD; GUANOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HOMOHARRINGTONINE; IMATINIB; ISOLEUCINE; JANUS KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PANOBINOSTAT; PHOSPHOPROTEIN PHOSPHATASE 2A; PONATINIB; RAC1 PROTEIN; RAC2 PROTEIN; RAF PROTEIN; RAS PROTEIN; STAT5 PROTEIN; STI 572; TANESPIMYCIN; TIPIFARNIB; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALOPECIA; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CELL CYCLE PROGRESSION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; ENZYME ACTIVITY; FEVER; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; LIVER TOXICITY; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; X RAY CRYSTALLOGRAPHY;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDAZINES; PYRIMIDINES; THIAZOLES;

EID: 79957464119     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0079-9     Document Type: Article

References (50)

1. A Quintas-Cardama J Cortes 2009 Molecular biology of bcr-abl1-positive chronic myeloid leukemia Blood 113 8 1619 30 18827185 10.1182/blood-2008-03- 144790 1:CAS:528:DC%2BD1MXisV2iurs%3D
2. M Baccarani J Cortes F Pane D Niederwieser G Saglio J Apperley, et al. 2009 Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 35 6041 51 19884523 10.1200/JCO.2009.25.0779 1:CAS:528:DC%2BC3cXhtVWisLY%3D
3. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009;114 (22), Abstract 1126
4. AJF Part 2007 Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 11 1018 29 10.1016/S1470-2045(07)70342-X (Pubitemid 47629897)
5. A Hochhaus M Baccarani M Deininger JF Apperley JH Lipton SL Goldberg, et al. 2008 Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 6 1200 6 18401416 10.1038/leu.2008.84 1:CAS:528: DC%2BD1cXntVCjurw%3D (Pubitemid 351833788)
6. HM Kantarjian F Giles N Gattermann K Bhalla G Alimena F Palandri, et al. 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 10 3540 6 17715389 10.1182/blood-2007-03-080689 1:CAS:528:DC%2BD2sXhtlarur3P (Pubitemid 350159618)
7. H Kantarjian NP Shah A Hochhaus J Cortes S Shah M Ayala, et al. 2010 Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 24 2260 70 20525995 10.1056/NEJMoa1002315 1:CAS:528:DC%2BC3cXnvVaktbY%3D
8. G Saglio DW Kim S Issaragrisil P le Coutre G Etienne C Lobo, et al. 2010 Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 24 2251 9 20525993 10.1056/NEJMoa0912614 1:CAS:528:DC%2BC3cXnvVaktbk%3D
9. RJ Garg H Kantarjian S O'Brien A Quintas-Cardama S Faderl Z Estrov, et al. 2009 The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up Blood 114 20 4361 8 19729517 10.1182/blood-2009-05-221531 1:CAS:528:DC%2BD1MXhsVGrsLvM
10. M Copland A Hamilton LJ Elrick JW Baird EK Allan N Jordanides, et al. 2006 Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 11 4532 9 16469872 10.1182/blood-2005-07-2947 1:CAS:528:DC%2BD28Xlt1CgtrY%3D (Pubitemid 43801382)
11. SM Graham HG Jorgensen E Allan C Pearson MJ Alcorn L Richmond, et al. 2002 Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 1 319 25 11756187 10.1182/blood.V99.1.319 1:CAS:528:DC%2BD38XivF2gug%3D%3D (Pubitemid 34532999)
12. HG Jorgensen EK Allan NE Jordanides JC Mountford TL Holyoake 2007 Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells Blood 109 9 4016 9 17213283 10.1182/blood-2006-11-057521 1:CAS:528:DC%2BD2sXkvFCiurc%3D (Pubitemid 46641755)
13. R Bhatia M Holtz N Niu R Gray DS Snyder CL Sawyers, et al. 2003 Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 12 4701 7 12576334 10.1182/blood-2002-09-2780 1:CAS:528:DC%2BD3sXkslequ7o%3D (Pubitemid 36857723)
14. T O'Hare WC Shakespeare X Zhu CA Eide VM Rivera F Wang, et al. 2009 AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 5 401 12 19878872 10.1016/j.ccr.2009.09.028
15. •• Cortes J, Talpaz M, Bixby D, Deininger M, Shah N, Flinn IW, et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (cml) and other hematologic malignancies: emerging safety and clinical response findings [abstract]. Blood. 2010;116 (21), Abstract 210. This abstract reports the results of a phase I clinical trial of ponatinib in patients with imatinib-refractory CML; ponatinib was found to have activity in T315I mutated disease.
16. M Carmena WC Earnshaw 2003 The cellular geography of aurora kinases Nat Rev Mol Cell Biol 4 11 842 54 14625535 10.1038/nrm1245 1:CAS:528: DC%2BD3sXpvFais7g%3D (Pubitemid 37411723)
17. D Ye G Garcia-Manero HM Kantarjian L Xiao S Vadhan-Raj MH Fernandez, et al. 2009 Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes to acute myeloid leukemia J Hematop 2 1 2 8 19669217 10.1007/s12308-008-0019-3
18. A Gontarewicz S Balabanov G Keller R Colombo A Graziano E Pesenti, et al. 2008 Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I Blood 111 8 4355 64 18268096 10.1182/blood-2007-09- 113175 1:CAS:528:DC%2BD1cXkvFeitrw%3D
19. TA Carter LM Wodicka NP Shah AM Velasco MA Fabian DK Treiber, et al. 2005 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc Natl Acad Sci USA 102 31 11011 6 16046538 10.1073/pnas.0504952102 1:CAS:528:DC%2BD2MXnvVWjurg%3D (Pubitemid 41105984)
20. Hoover RR, Harding MW. Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, ara-C, and inhibitors of BCR-ABL [abstract]. Blood. 2006;108 (11), Abstract 1384
21. MA Young NP Shah LH Chao M Seeliger ZV Milanov WH Biggs 3rd, et al. 2006 Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680 Cancer Res 66 2 1007 14 16424036 10.1158/0008-5472.CAN-05-2788 1:CAS:528:DC%2BD28XlsFOhtw%3D%3D (Pubitemid 43168337)
22. Giles F, Cortes J, Bergstrom DA, Xiao A, Bristow P, Jones D, et al. MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant chronic myelogenous leukemia (CML) [abstract]. Blood. 2006;108 (11), Abstract 163
23. Cortes J, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Latini F, et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia [abstract]. Blood. 2009;114 (22), Abstract 864
24. Brummendorf TH, Gontarewicz A, Keller G, Moll J, Braig M, Rohe I, et al. Resistance to danusertib (formerly PHA-739358) in BCR-ABL-positive cells is mediated by up regulation of the drug transporter Abcg2 and can be suppressed in vitro by combination treatment with imatinib [abstract]. Blood. 2009;114 (22), Abstract 1724
25. Shah NP, Kasap C, Paquette R, Cortes J, Pinilla J, Talpaz M, et al. Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228 [abstract]. Blood. 2007;110 (11), Abstract 47
26. J Cortes R Paquette M Talpaz J Pinilla E Asatiani M Wetzler, et al. 2008 Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF- 1R/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract] Blood 112 11 3232
27. S Howard V Berdini JA Boulstridge MG Carr DM Cross J Curry, et al. 2009 Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity J Med Chem 52 2 379 88 19143567 10.1021/jm800984v 1:CAS:528:DC%2BD1MXnt1Wn
28. R Tanaka MS Squires S Kimura A Yokota R Nagao T Yamauchi, et al. 2010 Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells Blood 116 12 2089 95 20548094 10.1182/blood-2009-03-211466 1:CAS:528:DC%2BC3cXht1KisbfM
29. Foran JM, Ravandi F, O'Brien SM, Borthakur G, Rios MB, Boone P, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia [abstract]. J Clin Oncol. 2008;26 (15S), Abstract 2518
30. Van Etten RA, Chan WW, Zaleskas VM, Evangelista P, Lazarides K, Peng C, et al. DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model [abstract]. Blood. 2007;110 (11), Abstract 463
31. J Cortes A Quintas-Cardama G Garcia-Manero S O'Brien D Jones S Faderl, et al. 2007 Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure Cancer 110 9 2000 6 17849425 10.1002/cncr.23006 1:CAS:528:DC%2BD2sXhtlertbrK (Pubitemid 350036859)
32. M Copland F Pellicano L Richmond EK Allan A Hamilton FY Lee, et al. 2008 BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood 111 5 2843 53 18156496 10.1182/blood-2007-09-112573 1:CAS:528:DC%2BD1cXivFakurg%3D
33. J Cortes S Faderl E Estey R Kurzrock D Thomas M Beran, et al. 2005 Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes J Clin Oncol 23 12 2805 12 15728224 10.1200/JCO.2005.09.005 1:CAS:528:DC%2BD2MXktleqtrc%3D (Pubitemid 46179471)
34. EK Thomas JA Cancelas HD Chae AD Cox PJ Keller D Perrotti, et al. 2007 Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease Cancer Cell 12 5 467 78 17996650 10.1016/j.ccr.2007.10.015 1:CAS:528:DC%2BD2sXhtl2nurrP (Pubitemid 350046406)
35. P Neviani R Santhanam R Trotta M Notari BW Blaser S Liu, et al. 2005 The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein Cancer Cell 8 5 355 68 16286244 10.1016/j.ccr.2005.10.015 1:CAS:528:DC%2BD2MXht12gsbvJ (Pubitemid 41579831)
36. P Neviani R Santhanam JJ Oaks AM Eiring M Notari BW Blaser, et al. 2007 FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia J Clin Invest 117 9 2408 21 17717597 10.1172/JCI31095 1:CAS:528:DC%2BD2sXhtVCms7vM This article explains a preclinical rationale for studying PP2A activators in CML (Pubitemid 47494343)
37. R Nimmanapalli E O'Bryan K Bhalla 2001 Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts Cancer Res 61 5 1799 804 11280726 1:CAS:528:DC%2BD3MXit1Ohur8%3D (Pubitemid 32691987)
38. ME Gorre K Ellwood-Yen G Chiosis N Rosen CL Sawyers 2002 BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 Blood 100 8 3041 4 12351420 10.1182/blood-2002-05-1361 1:CAS:528:DC%2BD38XotVGhtb4%3D
39. VM Richon S Emiliani E Verdin Y Webb R Breslow RA Rifkind, et al. 1998 A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proc Natl Acad Sci USA 95 6 3003 7 9501205 10.1073/pnas.95.6.3003 1:CAS:528:DyaK1cXitV2itro%3D (Pubitemid 28135844)
40. R Nimmanapalli L Fuino C Stobaugh V Richon K Bhalla 2003 Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells Blood 101 8 3236 9 12446442 10.1182/blood-2002-08-2675 1:CAS:528:DC%2BD3sXjtFCqtbg%3D (Pubitemid 36858020)
41. W Fiskus M Pranpat P Bali M Balasis S Kumaraswamy S Boyapalle, et al. 2006 Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells Blood 108 2 645 52 16537804 10.1182/blood-2005-11-4639 1:CAS:528: DC%2BD28XntFehtbk%3D (Pubitemid 44061366)
42. W Fiskus M Pranpat M Balasis P Bali V Estrella S Kumaraswamy, et al. 2006 Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells Clin Cancer Res 12 19 5869 78 17020995 10.1158/1078-0432.CCR-06-0980 1:CAS:528:DC%2BD28XhtVartbnM (Pubitemid 44629620)
43. R Nimmanapalli L Fuino P Bali M Gasparetto M Glozak J Tao, et al. 2003 Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells Cancer Res 63 16 5126 35 12941844 1:CAS:528:DC%2BD3sXms12ntro%3D (Pubitemid 37022654)
44. P George P Bali S Annavarapu A Scuto W Fiskus F Guo, et al. 2005 Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3 Blood 105 4 1768 76 15514006 10.1182/blood-2004-09-3413 1:CAS:528:DC%2BD2MXhsVGjsL4%3D (Pubitemid 40223701)
45. B Zhang AC Strauss S Chu M Li Y Ho KD Shiang, et al. 2010 Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate Cancer Cell 17 5 427 42 20478526 10.1016/j.ccr.2010.03.011 This article demonstrates that HDACI can target quiescent leukemic stem cells in CML
46. Guilhot F, Dubruille V, Skotnicki AB, Hellmann A, Shamsazar J, Bourquelot PM, et al. A phase II study of oral panobinostat (LBH589) in accelerated phase (AP) or blast crisis (BC) chronic myeloid leukemia (CML) patients resistant to >=2 BCR-ABL tyrosine kinase inhibitors [abstract]. Blood. 2008;112 (11), Abstract 4263
47. A Quintas-Cardama H Kantarjian J Cortes 2009 Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009 Cancer 115 23 5382 93 19739234 10.1002/cncr.24601 1:CAS:528:DC%2BD1MXhsFOmsb%2FK
48. R Tang AM Faussat P Majdak C Marzac S Dubrulle Z Marjanovic, et al. 2006 Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells Mol Cancer Ther 5 3 723 31 16546987 10.1158/1535-7163.MCT-05-0164 1:CAS:528:DC%2BD28Xitl2lu7w%3D
49. • Cortes J, Khoury HJ, Nicolini FE, Corm S, Lipton JH, Jones D, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr- Abl T315I mutation-results of an ongoing multicenter phase 2/3 study [abstract]. Blood. 2009;114 (22), Abstract 644. This abstract reports results of a phase 2 study of omacetaxine in patients with T315I-mutated CML.
50. Cortes J, Raghunadharao D, Parikh P, Wetzler M, Lipton JH, Jones D, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors-results of a multicenter phase 2/3 study [abstract]. Blood. 2009;114 (22), Abstract 861.